Name (Synonyms) | Correlation | |
---|---|---|
HP:0001626 | Abnormality of the cardiovascular system HPO | 1.00 |
There is one clinical trial.
The purpose of this clinical trial is to assess the safety and efficacy of Clevudine 120 mg once a day for 14 days (maximum up to 21 days) and of Hydroxychloroquine 200mg twice a day for 14 days (maximum up to 21 days) of administration in patients with moderate COVID-19.
Description: The primary efficacy endpoint for this clinical trial is the rate of patients with negative SARS-Coronavirus-2 (SARS-CoV-2) in a two-day continuous Real-Time-RT-PCR test from baseline to before the 15th day.
Measure: The rate of subjects tested as negative SARS-Coronavirus-2 (SARS-CoV-2) Time: within 15days